.Nature Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of clients with HER2+ advanced breast cancer cells as well as active or even stable human brain metastases presented regular intracranial task and also systemic effectiveness of T-DXd.